M229 |
In vitro naturally sensitive |
BRAFV600E homozygous |
|
|
AKT1 amplification |
|
|
PTEN heterozygous deletion |
M229-AR9 |
In vitro acquired resistance |
BRAFV600E homozygous |
|
|
AKT1 amplification |
|
|
PTEN heterozygous deletion |
M238 |
In vitro naturally sensitive |
BRAFV600E heterozygous |
|
|
PTEN heterozygous deletion |
|
|
CDKN2A homozygous deletion |
M238-AR2 |
In vitro acquired resistance |
BRAFV600E heterozygous |
|
|
PTEN heterozygous deletion |
|
|
CDKN2A homozygous deletion |
M249 |
In vitro naturally sensitive |
BRAFV600E heterozygous |
|
|
PTEN homozygous deletion |
M249-AR4 |
In vitro acquired resistance |
BRAFV600E heterozygous |
|
|
NRASQ61K heterozygous |
|
|
PTEN homozygous deletion |
M370 |
Patient-derived from a cardiac mass with acquired resistance |
BRAFV600E heterozygous |
M376 |
Patient-derived from a nodal metastasis with acquired resistance |
BRAFV600E heterozygous
|
|
|
NRASQ61K heterozygous
|
|
|
PTEN heterozygous deletion
|
M380 |
Patient-derived from a subcutaneous mass with natural resistance |
BRAFV600E heterozygous
|
|
|
CDKN2A homozygous deletion
|
M395 |
Patient-derived from an adrenal mass with acquired resistance |
BRAFV600E homozygous
|
|
|
CDKN2A homozygous deletion
|
M233 |
In vitro naturally resistant |
BRAFV600E heterozygous |
|
|
AKT1 amplification |
|
|
PTEN homozygous deletion |
M244 |
In vitro naturally resistant |
NRASQ61K heterozygous
|
M263 |
In vitro naturally resistant |
BRAFV600E heterozygous |